Tag: brokerswatch

Sep 22
Visa stock on track to extend longest losing streak since 2013

Visa Inc. shares V, -1.12% were off 0.7% in Thursday morning trading and on track to log their eighth-straight trading day of declines if the losses hold through the close. A close in the red Thursday would extend Visa’s longest losing streak since Aug. 16, 2013, according to Dow Jones Market Data. Shares fell for […]

Sep 22
Novavax stock extends plunge after J.P. Morgan turns bearish, on expectations of more guidance cuts

Shares of Novavax Inc. NVAX, -9.15% slumped 7.1% in morning trading Thursday, to extend their recent plunge toward a near 2 1/2-year low, after J.P. Morgan threw in the towel on the maker of the COVID-19 vaccine Nuvaxovid, citing expectations of more cuts to revenue guidance. Analyst Eric Joseph cut his rating to underweight, after […]

Sep 22
Traders price in 26% chance that fed-funds rate can get to 5% in March

Fed-funds futures traders now see a decent chance that U.S. policy makers will lift borrowing costs to a range between 4.75% to 5% by March, versus the current level between 3% and 3.25%. They see a 26% chance of such a scenario, up from 19% on Wednesday and zero likelihood a month ago, according to […]

Sep 22
Raymond James launches coverage of insurance companies with strong buys on three names

Raymond James on Thursday launched analyst coverage of six insurers, with Prudential Financial Inc. PRU, -0.11% (price target $115), Voya Financial Inc. VOYA, -0.77% (price target $84) and Globe Life Inc. GL, -0.08% (price target $138) all drawing strong buy ratings. Raymond James assigned market perform ratings to MetLife Inc. MET, -0.79%, Principal Financial Group […]

Sep 22
UBS: LIlly’s Type 2 diabetes and obesity treatment could be ‘one of the best-selling drugs in history’

Shares of Eli Lilly & Co. Inc. LLY, +2.04% gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company’s newly approved Type 2 diabetes drug, could be “the biggest drug ever.” UBS analysts predict peak sales of $25 billion if the therapy is also approved […]

Sep 22
The Big Apple keeps No. 1 ranking over London in the Global Financial Centres Index (GFCI)

New York City held on to its top ranking over No. 2 London among cities in the Global Financial Centres Index, Reuters reported Thursday, citing data from London-based think tank Z/Yen. Hong Kong fell to fourth place and Singapore moved up to third. Moscow’s ranking dropped to 73rd from 51 in the face of economic […]

Sep 22
Activist shareholder Ancora calls for Kohl’s board to replace chairman and CEO; says company on ‘dangerous trajectory’

Activist shareholder Ancora Holdings Group LLC on Thursday urged the board of Kohl’s Corp. KSS, +0.14% to replace its chairman Peter Boneparth and chief executive Michelle Gass with a leader with turnaround experience. In a letter to the board made public, Ancora said the retailer’s “botched strategic review, credit downgrade, dramatic decline in sales, elevated […]

Sep 22
Royal Caribbean stock gains after disclosing bookings were ‘significantly outpacing’ pre-pandemic levels

Shares of Royal Caribbean Group RCL, +1.49% rose 0.5% in premarket trading Thursday, after the cruise operator said demand remains “strong,” as bookings have been “significantly outpacing” pre-pandemic 2019 levels. The company said the easing of COVID-19 testing and vaccination requirements from most of its cruises had an “immediate positive impact” on bookings for 2022 […]

Sep 22
Talos Energy to acquire EnVen Energy for $1.1 billion in cash and stock

Talos Energy Inc. TALO, -4.16% said Thursday it has reached agreement to acquire privately held EnVen Energy Corp. for $1.1 billion cash and stock. Under the terms of the deal, EnVen shareholders will receive 43.8 million shares and $212.5 million in cash, along with the assumption of EnVen’s debt of about $50 million. Once the […]

Sep 22
Accenture stock falls after profit and revenue beat expectations but outlook was downbeat

Shares of Accenture PLC ACN, -1.78% dropped 0.9% toward an 18-month low in premarket trading Thursday, after the consulting company reported fiscal fourth-quarter profit and revenue that topped expectations but provided a downbeat outlook. Net income for the quarter to Aug. 31 rose to $1.67 billion, or $2.60 a share, from $1.42 billion, or $2.20 […]